Cathleen Phillips Davis

Nessuna posizione attualmente

70 anni

Health Technology

Consumer Services

Profilo

Cathleen Phillips Davis has been Vice President of Finance and Controller of Threshold Pharmaceuticals, Inc. since August 2006.
Previously, she was Controller of Threshold Pharmaceuticals from July 2005 to August 2006, Theravance, Inc. from 2002 to 2005 and ALZA Corporation from 1999 to 2002.
Ms. Davis received a BS degree in Business Administration from California State University, Hayward and became a Certified Public Accountant in 1993.

Precedenti posizioni note di Cathleen Phillips Davis

Società	Posizione	Fine
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Direttore Finanziario/CFO	02/11/2007

Vedi nel dettaglio l'esperienza di Cathleen Phillips Davis

Formazione di Cathleen Phillips Davis

California State University-East Bay

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Cathleen Phillips Davis

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Threshold Pharmaceuticals, Inc. Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA	Health Technology